Search

Your search keyword '"Shiojima, Ichiro"' showing total 393 results
Start Over Author "Shiojima, Ichiro" Language english
393 results on '"Shiojima, Ichiro"'

37. Serum Angiopoietin-Like Protein 2 and NT-Pro BNP Levels and Their Associated Factors in Patients with Chronic Heart Failure Participating in a Phase III Cardiac Rehabilitation Program

Author

Tanaka, Chiharu, Kurose, Satoshi, Morinaga, Jun, Takao, Nana, Miyauchi, Takumi, Tsutsumi, Hiromi, Shiojima, Ichiro, Oike, Yuichi, and Kimura, Yutaka

Subjects
Heart Failure, Inflammation, Male, Cardiac Rehabilitation, Exercise Tolerance, Anaerobic Threshold, Hand Strength, Stroke Volume, Blood Proteins, Middle Aged, Peptide Fragments, Ventricular Function, Left, Angiopoietin-like Proteins, C-Reactive Protein, Cross-Sectional Studies, Echocardiography, Case-Control Studies, Chronic Disease, Multivariate Analysis, Natriuretic Peptide, Brain, Body Composition, Humans, Female, Biomarkers, Aged
Abstract

令和3年度, Angiopoietin-like protein 2 (ANGPTL2) promotes chronic inflammation and plays a key role in the pathogenesis of heart failure. Cardiac rehabilitation (CR) is an integral component of heart failure management and has been shown to have anti-inflammatory effects. However, ANGPTL2 concentration in chronic heart failure patients undergoing CR has not been evaluated. This study aimed to investigate serum ANGPTL2 levels and their associated factors and compare the results with those of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with chronic heart failure undergoing phase III CR.A total of 56 patients were enrolled. Clinical characteristics including body composition, grip strength, exercise tolerance, duration of CR, blood counts and biochemistry, and echocardiographic parameters were evaluated for their association with serum ANGPTL2 and NT-proBNP levels.The median (first and third quartiles) value of ANGPTL2 was 4.05 (2.70-5.57) ng/mL. Clinical parameters that correlated with serum ANGPTL2 levels were body weight, body mass index, body fat mass, body fat percentage, anaerobic threshold (AT), C-reactive protein, and total protein (TP), which were mostly distinct from those that correlated with serum NT-proBNP levels. A multivariate analysis revealed that AT and TP were independent factors related to ANGPTL2 levels, whereas age, left ventricular ejection fraction, and left atrial dimension were independently related to NT-proBNP levels.These observations suggest that CR increases the exercise tolerance and exhibits anti-inflammatory effects simultaneously, and this situation is reflected by decreased serum ANGPLT2 and TP levels. ANGPTL2 may be a useful marker of inflammation and impaired exercise tolerance in patients with chronic heart failure.

Published
2021

39. H2ARDD score as a feasible predictor of heart failure events in patients with atrial fibrillation: a validation study.

Author

Taniguchi, Naoki, Miyasaka, Yoko, Suwa, Yoshinobu, Harada, Shoko, Nakai, Eri, and Shiojima, Ichiro

Subjects
HEART failure patients, ATRIAL fibrillation, HEART failure, ATRIAL flutter, HEART diseases, RECEIVER operating characteristic curves
Abstract

It was reported that the H2ARDD score (organic heart diseases = 2 points, anemia = 1 point, renal dysfunction = 1 point, diabetes = 1 point, and diuretic use = 1point; range 0 to 6 points) may help identify patients with AF at high risk for HF events. However, this score has not been externally validated. The objective of this study was to evaluate the usefulness of H2ARDD score in predicting HF events in patients with AF. We used a prospective database of patients with AF, and Cox-proportional hazards models were used to assess the risk of HF events. The outcome of interest was defined as HF events including new-onset HF and death from HF. Of 562 AF patients, 518 (mean 69.7 ± 9.7 years-old, 64.9% men) met study criteria, and 84 (16.2%) developed HF events during a mean follow–up of 54 ± 42 months. In multivariable analyses, H2ARDD score was shown as a significant predictor for HF events [hazard ratio (HR): 1.56, 95% confidence interval (CI): 1.36–1.79], independent of age (per 10 years, HR: 1.35, 95% CI: 1.03–1.78). In the Kaplan–Meier analyses stratified by H2ARDD score categories (0–2, 3–4, 5–6), the patients with higher H2ARDD scores had significantly worse HF event-free survival (log-rank P < 0.0001). The area under the ROC curve was 0.71 (95% CI: 0.65–0.77, P < 0.0001). The sensitivity and specificity at a cut-off score of ≥ 3 were 60% and 71%, respectively. In conclusion, the H2ARDD score may be feasible for HF risk stratification in patients with AF. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Complement C1q Activates Canonical Wnt Signaling and Promotes Aging-Related Phenotypes

Author

Naito, Atsuhiko T., Sumida, Tomokazu, Nomura, Seitaro, Liu, Mei-Lan, Higo, Tomoaki, Nakagawa, Akito, Okada, Katsuki, Sakai, Taku, Hashimoto, Akihito, Hara, Yurina, Shimizu, Ippei, Zhu, Weidong, Toko, Haruhiro, Katada, Akemi, Akazawa, Hiroshi, Oka, Toru, Lee, Jong-Kook, Minamino, Tohru, Nagai, Toshio, Walsh, Kenneth, Kikuchi, Akira, Matsumoto, Misako, Botto, Marina, Shiojima, Ichiro, and Komuro, Issei

Published
2012
Full Text
View/download PDF

49. Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction - The CIBIS-J Trial

Author

Tsutsui, Hiroyuki, Momomura, Shin-ichi, Masuyama, Tohru, Saito, Yoshihiko, Komuro, Issei, Murohara, Toyoaki, Kinugawa, Shintaro, Oba, Koji, Sato, Norihiro, Yasumura, Yoshio, Hiramitsu, Shinya, Satou, Yukihito, Inomata, Takayuki, Onishi, Katsuya, Sakata, Yasushi, Mizuno, Kyoichi, Sunagawa, Kenji, Ogawa, Hisao, Isobe, Mitsuaki, Daida, Hiroyuki, Kurabayashi, Masahiko, Kohya, Tetsuro, Ogawa, Yuji, Itoh, Naofumi, Kakinoki, Shigeo, Aoki, Kenji, Tsuchida, Akihito, Ito, Hiroshi, Yamaguchi, Osamu, Eki, Yutaka, Toyoda, Shigeru, Nakano, Akihiko, Koitabashi, Norimichi, Muramatsu, Toshihiro, Nakahara, Hideo, Tanaka, Hiroyuki, Yamashina, Akira, Takasu, Kiyoshi, Maejima, Yasuhiro, Momiyama, Yukihiko, Nakamura, Iwao, Kida, Keisuke, Naruke, Takashi, Takenobu, Hideshi, Minamino, Tohru, Nakamura, Masahiko, Ikeda, Masatoshi, Ashida, Kazuhiro, Takahashi, Shigekiyo, Minatoguchi, Shinya, Suwa, Satoru, Satoh, Hiroshi, Izawa, Hideo, Fukuta, Hidekatsu, Tsuboi, Naoya, Uzui, Hiroyasu, Wada, Atsuyuki, Kimura, Takeshi, Takenaka, Ken, Kato, Takao, Okutsu, Masaaki, Ohtani, Tomohito, Hasegawa, Shinji, Anzai, Toshihisa, Fujii, Kenshi, Shiojima, Ichiro, Yasaka, Yoshinori, Hirata, Ken-ichi, Akasaka, Takashi, Kihara, Yasuki, Tamura, Ritsu, Teragawa, Hiroki, Yasuda, Kotaro, Okuhara, Koichiro, Karashima, Eiji, Sata, Masataka, Ota, Akira, Noma, Takahisa, Suzuki, Jun, Watanabe, Kouki, Kitaoka, Hiroaki, Matsukawa, Ryuichi, Yoshihiro, Takeshi, Tanaka, Nobuhide, Ozumi, Kiyoshi, Takahashi, Masaru, Maemura, Koji, and Atsuchi, Nobuhiko

Subjects
Adult, medicine.medical_specialty, Heart failure, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Japan, Heart Rate, Internal medicine, Heart rate, Natriuretic Peptide, Brain, Clinical endpoint, medicine, Humans, Bisoprolol, 030212 general & internal medicine, Carvedilol, Aged, Aged, 80 and over, Ejection fraction, business.industry, Maintenance dose, Stroke Volume, General Medicine, Middle Aged, medicine.disease, Tolerability, Treatment Outcome, Cardiology, beta-blocker, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

Background: The comparative tolerability, efficacy, and safety of bisoprolol and carvedilol have not been established in Japanese patients with heart failure and reduced ejection fraction (HFrEF). Methods and Results: The CIBIS-J trial is a multicenter, open-label, non-inferiority randomized controlled trial of bisoprolol vs. carvedilol in 217 patients with HFrEF (EF

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results